Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Context: GH deficiency (GHD) may occur in adults with cured acromegaly (acroGHD). Objective: Our objective was to examine the effectiveness and safety of GH replacement in acroGHD. Design: This study was a retrospective analysis of data from KIMS (Pfizer International Metabolic Database). Setting: Data were extracted from a pharmaco-epidemiological survey of >16 000 GHD adults from 31 countries. Patients: The effectiveness population included 115 adults with acroGHD and 142 age-, gender-, and body mass index-matched GHD adults with nonfunctioning pituitary adenoma (NFPA) followed up to 5 years on GH. The safety population included 164 adults with acroGHD and 2469 with NFPA, all GH-replaced. Both acroGHD and NFPA were compared with several cohorts from the general population (including the World Health Organization Global Burden of Disease). Outcome Measures: Outcome measures included quality of life (QoL-AGHDA), lipids, serious adverse events, and additional safety endpoints. Results: Median GH dose was 0.3 mg/d in acroGHD and NFPA at 5 years. There were comparable improvements in QoL-AGHDA and total and low-density lipoprotein cholesterol in acroGHD and NFPA. High-density lipoprotein cholesterol increased only in acroGHD. Cardiovascular mortality was increased in acroGHD vs NFPA (standardized mortality ratio = 3.03, P = .02). All-cause mortality was similar in acroGHD (ratio between observed/expected cases [95% confidence interval] = 1.32 [0.70–2.25]) and lower in NFPA [observed/expected = 0.58 [0.48–0.70]) in comparison with the general population. There was no difference in incidence of all cancers, benign or malignant brain tumors, or diabetes mellitus between acroGHD and NFPA. Conclusions: GH replacement has comparable effects on quality of life and lipids in acroGHD and NFPA. Further investigation is needed to examine whether the increased cardiovascular mortality may be attributed to the history of previous GH excess in acroGHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A prospective study of 42 subjects reported that GH replacement enhanced QOL and improved both body composition and lipid profiles (232).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [232]
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Statistical methods in cancer research
Gardner, B. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1170 · Cited by 777
Ho, K. K. Y., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0631 · Cited by 615
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Research works printed but not linked: 1
- Mathers, 2003, Global burden of disease in 2002: data sources, methods and results, 1
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
Petrossians, P., Daly, A. F., Natchev, E., Maione, L., Blijdorp, K., Sahnoun-Fathallah, M., Auriemma, R., Diallo, A. M., Hulting, A.-L., Ferone, D., et al. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0253 · Cited by 263
Long‐term safety of growth hormone—A combined registry analysis
Stochholm, K., & Kieß, W. (2017) · Clinical Endocrinology · doi:10.1111/cen.13502 · Cited by 81
Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]
Giovannini, L., Tirabassi, G., Muscogiuri, G., Somma, C. D., Colao, A., & Balercia, G. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0337 · Cited by 64
Metadata
- Authors
- Tritos, N. A., Johannsson, G., Korbonits, M., Miller, K. K., Feldt-Rasmussen, U., Yuen, K. C. J., King, D., Mattsson, A. F., Jonsson, P. J., Koltowska-Haggstrom, M., Klibanski, A., & Biller, B. M. K.
- Affiliations
- Harvard University (US)
- Department of Endocrinology (G.J.), Gothenburg, Sweden SE-41345;
- Queen Mary University of London (GB)
- Department of Medical Endocrinology (U.F.-R.), Rigshospitalet, National University Hospital, Copenhagen University, Copenhagen, Denmark DK-2100;
- Oregon Health & Science University (US)
- Pfizer (United States) (US)
- Sahlgrenska University Hospital (SE)
- Pfizer Endocrine Care (P.J.J., M.K.-H.), Sollentuna, Sweden SE-19091
- Corresponding author
- Tritos, Nicholas A.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-06-01
- Volume
- 99
- Issue
- 6
- Pages
- 2018-2029
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2110254569
- Semantic Scholar
- 0edb100ad91356528e24d024cbe0b2264dbb00eb
- Cited by
- 31
- References
- 59
- Citations by year
- 2023: 3 · 2022: 7 · 2021: 1 · 2020: 3 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 6 · 2014: 2
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- growth hormone replacement therapy, acromegaly, non-functioning pituitary adenoma, quality of life, lipids, cardiovascular mortality, all-cause mortality, serious adverse events, cancer incidence, diabetes mellitus, brain tumors
- MeSH terms
- Acromegaly, Adult, Aged, Female, Follow-Up Studies, Humans, Hypopituitarism, Male, Middle Aged, Remission Induction, Retrospective Studies, Databases, Factual, Treatment Outcome, Human Growth Hormone, Hormone Replacement Therapy, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. https://app.cochat.ai/papers/10.1210/jc.2014-1013
- The paper
- Tritos, N. A., Johannsson, G., Korbonits, M., Miller, K. K., Feldt-Rasmussen, U., Yuen, K. C. J., King, D., Mattsson, A. F., Jonsson, P. J., Koltowska-Haggstrom, M., Klibanski, A., & Biller, B. M. K. (2014). Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2014-1013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.